Patients living with type 2 diabetes face a high risk of developing liver disease, yet screening rates remain low and cases often go undetected until advanced symptoms appear. Medical experts emphasize the urgent need for routine fibrosis risk assessment to catch metabolic dysfunction-associated steatotic liver disease early.
MASLD affects roughly seven in 10 individuals living with type 2 diabetes. According to Mary E. Rinella, a transplant hepatologist and director of the Metabolic Liver Clinic at University of Chicago Medicine, awareness of this critical connection remains very low. People with type 2 diabetes carry an elevated risk of developing metabolic dysfunction-associated steatotic liver disease, commonly known as MASLD, which occurs when excess fat builds up in the liver.
Without proactive screening, fat accumulation can advance to metabolic dysfunction-associated steatohepatitis, or MASH, triggering inflammation, liver damage, and scarring known as cirrhosis. The condition frequently progresses without noticeable symptoms in its early stages.
The liver manages blood sugar by storing extra glucose after meals and releasing it overnight, but a liver affected by fat deposits or scarring becomes less responsive to insulin signals. When you have type 2 diabetes, your body encounters difficulty utilizing insulin properly. This insulin resistance forms the foundation of type 2 diabetes, establishing a loop where diabetes and fatty liver disease compound one another.
Fernando K. and Professor Michael Roden, a professor of internal medicine at the German Diabetes Center, highlight that measuring the FIB-4 index during annual or biennial reviews can effectively identify patients who require further evaluation. The FIB-4 score uses routine blood test results to assess liver fibrosis risk.
Implementing Noninvasive Blood Tests in Routine Diabetes Care
A study published in the Canadian Liver Journal found that conventional fibrosis tools like FIB-4 are less reliable in patients with diabetes. Researchers noted that screening for MASLD should become a standard quality metric that primary care physicians document at every visit. Risk stratification in high-risk populations, including people with T2D, should also become a standard quality metric that endocrinologists document at every visit. Under recommended clinical pathways, patients with a low FIB-4 score can undergo periodic reassessment, while intermediate scores warrant additional evaluation through elastography. Individuals with high FIB-4 scores should be referred directly to a hepatologist. Rinella also advocates for routine FIB-4 testing for every person diagnosed with diabetes to prevent the progression from simple steatosis to severe cirrhosis.
Eating Balanced Diets and Exercising Regularly Improve Metabolic Health
Guidance from healthcare professionals highlights that balanced eating patterns, such as a Mediterranean-style diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats, support blood sugar regulation. These balanced eating patterns also support liver health. Regular physical activity, such as aiming for at least 150 minutes of movement weekly, helps the body utilize blood sugar more effectively and reduces stored liver fat.
Evaluating Emerging Pharmacological Options for MASH
Studies indicate that tirzepatide significantly reduces liver fat. Experimental agents like retatrutide show promise in halting and potentially reversing the progression of metabolic liver disease.
Earlier coverage: Why Non-Drinkers Get Fatty Liver and How to Reverse It Through Lifestyle Changes
